NASDAQ:SVRA Savara Q4 2024 Earnings Report $5.38 +0.11 (+2.09%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$5.38 0.00 (-0.09%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Savara EPS ResultsActual EPS-$0.13Consensus EPS -$0.11Beat/MissMissed by -$0.02One Year Ago EPSN/ASavara Revenue ResultsActual Revenue$0.27 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASavara Announcement DetailsQuarterQ4 2024Date3/27/2025TimeBefore Market OpensConference Call DateWednesday, March 26, 2025Conference Call Time8:00PM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Savara Earnings HeadlinesWhat is HC Wainwright's Estimate for Savara FY2029 Earnings?August 15 at 2:28 AM | americanbankingnews.comSavara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street ZenAugust 15 at 1:55 AM | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.August 15 at 1:00 AM | Weiss Ratings (Ad)Savara (SVRA) to Post Earnings on WednesdayAugust 11, 2026 | americanbankingnews.comSavara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed BumpAugust 5, 2026 | seekingalpha.comSavara (SVRA) Gets a Buy from Piper SandlerJuly 24, 2026 | theglobeandmail.comSee More Savara Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email. Email Address About SavaraSavara (NASDAQ:SVRA) (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need. The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications. Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.View Savara ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
